Algernon Pharmaceuticals Archives

Psychedelics News

Algernon Pharmaceuticals

Industry

8 Aug 2023

Algernon NeuroScience Announces Phase 2 DMT Stroke Study

Algernon NeuroScience has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study....

By Microdose NewsDesk

Industry

18 Jan 2023

Microdosing DMT to Treat Strokes: Not as Trippy as it Sounds

On January 17th, the company Algernon Pharmaceuticals announced that they had dosed the first patient in their Phase 1 safety trial of the psychedelic drug DMT to treat stroke patients....

By James Hallifax

Industry

17 Jan 2023

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

Algernon Pharmaceuticals subsidiary, Algernon NeuroScience, has dosed the first subject in its Phase 1 clinical study of an intravenous formulation of DMT in the Netherlands....

By Microdose NewsDesk

Industry

11 Jan 2023

Algernon Pharmaceuticals Announces Plans for 180 Patient Phase 2b Study

Algernon continues to move its programs forward, as it announces plans for a 180 patient, 90-day Phase 2b clinical study of NP-120 (“Ifenprodil”) for chronic cough to begin in Q3...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

28 Dec 2022

2022 Review: 3 Trials Pushing Boundaries of Psychedelic Medicine

James Hallifax takes a look at 3 psychedelic Clinical Trials Pushing Boundaries of Psychedelic Medicine in 2022...

By James Hallifax

Events

21 Nov 2022

Wonderland 2022 Recap: Algernon Pharmaceuticals

Algernon Pharmaceuticals was the Headline Sponsor for Wonderland: Miami 2022, ; presenting their work on DMT for stroke...

By Microdose

Industry

24 Oct 2022

Algernon Partners with Yale University for DMT Phase 2 Depression Trial

Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study...

By Microdose NewsDesk

Industry

20 Oct 2022

Microdose Announces Algernon Pharmaceuticals as Wonderland 2022 Headline Sponsor

It’s an honor for Microdose to announce Algernon Pharmaceuticals as the Headline Sponsor for Wonderland: Miami 2022....

By Microdose

Industry

12 Sep 2022

Algernon Pharmaceuticals Receives Approval for Phase 1 DMT Study

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study...

By Microdose

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result